These results provide empirical groundwork for developing effective evidence-based meditation protocols for psychedelic preparation. They also highlight the importance of considering psychedelic users’ level of previous meditation experience in optimising such interventions.

There is a push to shrink the anticipated 17-year research-to-practice gap for psychedelic-assisted therapy (PAT), offering precarious hope to those with disabling mental health conditions.

Anyone hoping the psychedelic community would come together in cosmic oneness after the Great Lykos Schism of 2024 may be disappointed, as the confirmation of Robert F Kennedy Junior as Secretary of Health and Human Services last week provoked starkly-polarised reactions from the field.

Perceptions of health outcomes following psychedelic use were broadly positive, and psilocybin was reported to be the most effective substance for both physical and mental health symptoms.

Psilocybin assisted psychotherapy for methamphetamine use disorder was feasible to implement in an outpatient setting, did not appear to generate safety concerns, and demonstrated signals of effectiveness warranting further investigation.

We only added 11 (January) studies to the database. More studies than ever are reviews, commentaries, and perspectives. Though they can provide a great introduction for a specific audience.

Confidence in negative self-beliefs decreased following 25 mg psilocybin. Entropy and subjective effects under 25 mg psilocybin correlated with decreases in negative self-belief confidence (acutely and at 4-weeks). Particularly strong evidence was seen for a relationship between decreases in negative self-belief confidence and increases in well-being.

This study describes Oregon’s early psilocybin facilitator workforce and assesses state-approved training programs.

This overview seeks to map out drug discovery & development activity in psychedelics. Candidates currently undergoing clinical trials are presented first, while those that are at the discovery or preclinical stage are catalogued in the latter half of this page.

The US FDA has approved a supplemental new drug application allowing esketamine nasal spray to be used as a standalone treatment in adults with major depressive disorder who have not responded adequately to at least two oral antidepressants.

The January edition of the American Journal of Bioethics focuses just on psychedelics. There are a couple of editorials and then four 'target articles' with a further twenty six article commentaries.

Group psilocybin-assisted therapy plus MBSR was associated with clinically significant improvement in depressive symptoms without serious adverse events and with greater reduction in symptoms than MBSR alone.

The body of IFS literature is extensive, enthusiastic, and thought-provoking. Outcome data for applying the model to Post-Traumatic Stress Disorder are limited.

The primary benefit of such a (Compass Pathways) framework is to support a safe and meaningful psilocybin experience. It also enables future research on the facets of psychological support and/or psychotherapy that most optimally complement psilocybin treatment.

We are delighted to introduce this special issue of the American Journal of Psychiatry on psychedelics. This marks a moment of legitimacy for what was once considered a fringe, fledgling movement driven solely by a select group of zealously dedicated scientists and clinicians. In contrast to this early nascent period, the enthusiasm, interest, and pursuit of scientific and medical research on the psychiatric applications of psychedelic compounds has exploded in recent years, leading to the declaration of the current phase as a “renaissance” period for psychedelic research.

After a course of MDMA-AT involving three MDMA administrations supported by psychotherapy, 67%–71% of individuals with PTSD no longer meet diagnostic criteria after MDMA-AT versus 32%–48% with placebo-assisted therapy, and effects endure at long-term follow-up ... This review further describes the putative neurobiological mechanisms of MDMA underlying its therapeutic effects, the clinical evidence of MDMA-AT, considerations at the level of public health and policy, and future research directions.

The Microdose asked a handful of journalists who closely follow and regularly report on the psychedelics beat to answer a few questions: 'What is one psychedelics story you will be following in 2025? Why?'

The FDA has granted the application priority review and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 11, 2024 to make the review determination.